MY160922A - Polyethylene glycol conjugated blood coagulation factor vii - Google Patents

Polyethylene glycol conjugated blood coagulation factor vii

Info

Publication number
MY160922A
MY160922A MYPI2012004710A MYPI2012004710A MY160922A MY 160922 A MY160922 A MY 160922A MY PI2012004710 A MYPI2012004710 A MY PI2012004710A MY PI2012004710 A MYPI2012004710 A MY PI2012004710A MY 160922 A MY160922 A MY 160922A
Authority
MY
Malaysia
Prior art keywords
polyethylene glycol
blood coagulation
factor vii
coagulation factor
glycol conjugated
Prior art date
Application number
MYPI2012004710A
Other languages
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY160922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of MY160922A publication Critical patent/MY160922A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MYPI2012004710A 2010-04-30 2011-04-28 Polyethylene glycol conjugated blood coagulation factor vii MY160922A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII

Publications (1)

Publication Number Publication Date
MY160922A true MY160922A (en) 2017-03-31

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2012004710A MY160922A (en) 2010-04-30 2011-04-28 Polyethylene glycol conjugated blood coagulation factor vii

Country Status (26)

Country Link
US (1) US20130150302A1 (enExample)
EP (1) EP2563402A1 (enExample)
JP (1) JP5870088B2 (enExample)
KR (1) KR20130055619A (enExample)
CN (1) CN102939108A (enExample)
AP (1) AP2012006575A0 (enExample)
AU (1) AU2011247147B2 (enExample)
BR (1) BR112012027590A2 (enExample)
CA (1) CA2797058A1 (enExample)
CL (1) CL2012003039A1 (enExample)
CO (1) CO6660443A2 (enExample)
CR (1) CR20120579A (enExample)
EA (1) EA201290938A1 (enExample)
EC (1) ECSP12012314A (enExample)
GB (2) GB201007357D0 (enExample)
IL (1) IL222566A (enExample)
MX (1) MX2012012683A (enExample)
MY (1) MY160922A (enExample)
NI (1) NI201200160A (enExample)
NZ (1) NZ603939A (enExample)
PE (1) PE20130254A1 (enExample)
PH (1) PH12012502150A1 (enExample)
RU (1) RU2012144555A (enExample)
SG (1) SG184906A1 (enExample)
WO (1) WO2011135307A1 (enExample)
ZA (1) ZA201208989B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
EA033469B1 (ru) 2012-04-16 2019-10-31 Cantab Biopharmaceuticals Patents Ltd Подкожное введение конъюгатов факторов крови с полиэтиленгликолем
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
KR102575788B1 (ko) 2018-05-18 2023-09-08 정저우 젠사이언시스 인코포레이티드 개선된 fviii 융합 단백질 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2572733A1 (en) * 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
LT1824988T (lt) * 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
PL1835938T3 (pl) * 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
KR20110016440A (ko) * 2008-04-24 2011-02-17 셀틱 파르마 피이지 엘티디. 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
CN102099058B (zh) * 2008-07-21 2014-10-22 宝力泰锐克斯有限公司 用于缀合生物分子的新试剂和方法
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Also Published As

Publication number Publication date
GB2492935B8 (en) 2014-10-29
BR112012027590A2 (pt) 2016-08-09
SG184906A1 (en) 2012-11-29
CA2797058A1 (en) 2011-11-03
GB2492935A (en) 2013-01-16
MX2012012683A (es) 2013-04-03
CL2012003039A1 (es) 2014-01-24
JP2013525414A (ja) 2013-06-20
HK1173946A1 (en) 2013-05-31
WO2011135307A1 (en) 2011-11-03
IL222566A (en) 2017-12-31
KR20130055619A (ko) 2013-05-28
PH12012502150A1 (en) 2013-02-04
RU2012144555A (ru) 2014-06-10
GB201220667D0 (en) 2013-01-02
PE20130254A1 (es) 2013-03-16
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
AP2012006575A0 (en) 2012-12-31
CR20120579A (es) 2013-04-25
GB2492935A8 (en) 2014-10-29
US20130150302A1 (en) 2013-06-13
GB2492935B (en) 2014-04-30
GB201007357D0 (en) 2010-06-16
IL222566A0 (en) 2012-12-31
AU2011247147B2 (en) 2014-09-18
NZ603939A (en) 2013-08-30
CO6660443A2 (es) 2013-04-30
JP5870088B2 (ja) 2016-02-24
CN102939108A (zh) 2013-02-20
EP2563402A1 (en) 2013-03-06
ZA201208989B (en) 2014-02-26
NI201200160A (es) 2013-04-19
ECSP12012314A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
MY160922A (en) Polyethylene glycol conjugated blood coagulation factor vii
MY160510A (en) Polyethylene gycol conjugated blood coagulation factor viia
MX362432B (es) Variantes de oxm pegilada.
AU335964S (en) Surgical stent
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
PH12013502192A1 (en) Antibodies against human angiopoietin 2
EP4406557A3 (en) Materials and methods for improving gastrointestinal function
BR112012010037A2 (pt) artigo de tubo médico
WO2014058804A3 (en) Micronized compositions composed of bone grafts and methods of making and using the same
PH12012501522A1 (en) Oral care compositions
PH12012501620A1 (en) Oral care compositions
EP2643009A4 (en) COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES
WO2011005510A3 (en) Peptide conjugates and uses thereof
IN2014MN02248A (enExample)
UA112420C2 (uk) Інгібітори апоптозу та їх застосування
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
UA103290C2 (ru) Фармацевтическая композиция ибупрофена для инъекции
GEP20125618B (en) Biodegradable copolymers of poly (ester urea) and method for obtaining same
DE602006020155D1 (de) Pharmazeutische wundheilungs-zusammensetzungen in ren und natriumhyaluronat
GB201004677D0 (en) New salt
UA109646C2 (uk) Терапевтичне застосування кон'югатів білка з полімером
WO2011083112A3 (en) Solid oral dosage form containing olmesartan medoxomil
UA54860U (ru) Лекарственный состав для обработки лунки зуба после атипичного удаления
GB201013343D0 (en) Compositions and methods for inducing platelet aggregation
HK1175999B (en) Polyethylene glycol conjugated blood coagulation factor viia